Jakob Begun

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 224 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +12

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 83 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Matthew C. Choy, C Li Wai Suen, Danny Con et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 52 citations

Pharmacy, Internal Medicine, Pharmacotherapy +12